This role leads the Global Quality Auditing (GQA) teams responsible for executing audits of operating units in Clinical Development (GCP), ATPLV: ADME (Absorption, Distribution, Metabolism, and Excretion), Toxicology, PK/PD (Pharmacokinetics/Pharmacodynamics), LEM (Laboratory for Experimental Medicine), Veterinary Resources (GLP), Global Patient Safety/Pharmacovigilance (GVP), Regulatory Affairs and Product Quality, including conducting GxP audits of operations in Lilly’s affiliates. These audits serve to ensure that research conducted and sponsored by the Company, as well as product and disease state information shared with customers are in accordance with Company policies, practices and procedures and in compliance with current regulations and guidelines.
The broad scope of auditing managed by the Sr. Director requires that the Sr. Director provides strategic input to the overall GQA audit program and interacts effectively with global quality leadership and business unit stakeholders. The Sr. Director is responsible for staying abreast of the changing environment, both internal business priorities and external regulatory expectations, to identify and focus continuous improvement efforts.